MARKET

PCRX

PCRX

Pacira BioSciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

55.94
+0.78
+1.41%
After Hours: 55.94 0 0.00% 16:31 09/17 EDT
OPEN
55.53
PREV CLOSE
55.16
HIGH
56.02
LOW
54.83
VOLUME
592.21K
TURNOVER
--
52 WEEK HIGH
80.00
52 WEEK LOW
48.23
MARKET CAP
2.49B
P/E (TTM)
14.32
1D
5D
1M
3M
1Y
5Y
Pacira BioSciences Reports Preliminary Net Product Sales of $42.3 Million for August 2021
-- Expanding EXPAREL utilization continues to drive growth with average daily sales at 109% of August 2020 --
GlobeNewswire · 2d ago
Pacira's August Exparel Sales Rise 15% From Year Ago
MT Newswires · 2d ago
Pacira BioSciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the H.C. Wainwright 23 Annual Global Investment Conference at 7:00 AM ET on Monday, September 13, 2021. Pre-recorded audio of the virtual event can be accessed by visiting the ...
GlobeNewswire · 09/08 12:00
Advisors' Inner Circle Fund III Buys Signet Jewelers, Covetrus Inc, Green Plains Inc, Sells ...
GuruFocus News · 09/04 08:38
Pacira (PCRX) Down 1.6% Since Last Earnings Report: Can It Rebound?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks · 09/02 15:31
Tygh Capital Management, Inc. Buys Rapid7 Inc, Kirby Corp, Pennant Group Inc, Sells The Shyft ...
GuruFocus News · 08/13 20:38
BRIEF-Pacira Biosciences Reports Preliminary Net Product Sales Of $42.1 Million For July 2021
reuters.com · 08/10 13:08
Pacira BioSciences Reports Preliminary Exparel Sales Of $40.9 Million In July
MT Newswires · 08/10 12:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PCRX. Analyze the recent business situations of Pacira BioSciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PCRX stock price target is 79.00 with a high estimate of 95.00 and a low estimate of 54.00.
EPS
Institutional Holdings
Institutions: 378
Institutional Holdings: 52.63M
% Owned: 118.38%
Shares Outstanding: 44.45M
TypeInstitutionsShares
Increased
95
3.32M
New
23
476.23K
Decreased
81
3.60M
Sold Out
30
441.03K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Chief Executive Officer/Director
David Stack
Chief Financial Officer
Charles Reinhart
Corporate Executive
Max Reinhardt
Chief Administrative Officer/Secretary
Kristen Williams
Other
Charles Laranjeira
Other
Dennis McLoughlin
Other
Roy Winston
Lead Director/Independent Director
Paul Hastings
Director
Christopher Christie
Independent Director
Laura Brege
Independent Director
Mark Froimson
Independent Director
Yvonne Greenstreet
Independent Director
Mark Kronenfeld
Independent Director
John Longenecker
Independent Director
Gary Pace
Independent Director
Andreas Wicki
No Data
  • All
  • Financials
  • Insiders
More
About PCRX
Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Webull offers kinds of Pacira Biosciences Inc stock information, including NASDAQ:PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.